"Kazia Therapeutics (KZIA) reported results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care for patients with glioblastoma. The company said the GBM AGILE trial data showed clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma.
Kazia CEO, John Friend said, "We are excited to have shown a 3.8 month improvement in overall survival, an approximate 33% improvement, for newly diagnosed unmethylated patients with GBM compared to the concurrent standard of care arm. Having comparable Overall Survival data across two independent studies is a compelling outcome in this difficult to treat glioblastoma population."
"
https://www.nasdaq.com/articles/kazia-paxalisib-phase-ii-iii-data-shows-improvement-overall-survivalTurns out Agile study was still a good story. Always said nothing has changed and that it was a huge mistake to sell off news that was not very clear to interpret.